Compare Novavax Inc (NVAX) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Materials Select Sector SPDR Fund — how do they compare? Novavax Inc trades at $12.93 (market cap $1.82B), while Materials Select Sector SPDR Fund trades at $49.47 (market cap $7.73B). The key difference: Materials Select Sector SPDR Fund is far larger — about 4.2× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Materials Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Materials Select Sector SPDR Fund for 70 Days on average.
| NVAX | XLB | |
|---|---|---|
Market Cap | $1.82B | $7.73B |
Volume | 6,198,505 | 13,681,146 |
Sector | Health | — |
52-Week High | $12.56 | $53.67 |
52-Week Low | $6.22 | $42.23 |
Typical Hold Time | 59 Days | 70 Days |
Enterprise Value | $1.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
XLB, the Materials Select Sector SPDR ETF, trades at $49.55, up 1.16% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The fund is heavily concentrated in chemicals (49% of assets) and faces cyclical pressures, with recent news highlighting sector volatility amid AI-driven infrastructure demand. Key support sits at $48, while resistance is at $50.
The outlook for XLB is cautious due to sector overvaluation concerns and bearish technicals. Opportunities lie in long-term infrastructure trends, but risks include economic sensitivity and high concentration. Investors should weigh cyclical exposure against potential growth from manufacturing and AI-related material demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
